30Mar 2023
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

The article discusses the potential benefits of glucagon-like peptide 1 (GLP1) receptor agonists in reducing cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and obesity. GLP1R agonists have been shown to reduce weight, blood pressure, and inflammation, and have been found to reduce major adverse cardiovascular events in patients with T2DM. The article also discusses the potential mechanisms by which GLP1R agonists may protect the cardiovascular system, and highlights emerging GLP1-based multi-agonists currently in development. Understanding these mechanisms will help optimize the therapeutic use and development of GLP1-based therapies with improved cardiovascular safety

  • #cardiology

Like

Save

Share